Market Research

Italy Point-of-Care Glucose Testing Market By Product Type (Lancing Devices and Strips, Blood-Glucose Meter), By Application (Type-1 Diabetes, Type-2 Diabetes), By End User (Hospitals and Clinics, Home Care Settings, Others): Opportunity Analysis and Indu

Best Price Guarantee Length Publisher Published Date SKU
from $2,670 79 Pages Allied Market Research June, 2023 ALMR18790517
Best Price Guarantee
Price from $2,670
Length 79 Pages
Publisher Allied Market Research
Published Date June, 2023
SKU ALMR18790517

Italy Point-of-Care Glucose Testing Market By Product Type (Lancing Devices and Strips, Blood-Glucose Meter), By Application (Type-1 Diabetes, Type-2 Diabetes), By End User (Hospitals and Clinics, Home Care Settings, Others): Opportunity Analysis and Industry Forecast, 2023-2032


The Italy point-of-care glucose testing market has been witnessing significant growth during the forecast period, owing to increase in innovation and rise in technological advancement. Moreover, the continuous pursuit for accurate and user-friendly glucose testing tools is a key factor driving the market growth. However, challenges regarding reimbursements and the inherent intricacies of diabetes management are the key factors restraining the growth of the Italy point-of-care glucose testing market. The Italy point-of-care glucose testing market is segmented into product type, application, and end user. On the basis of product type, the market is classified into lancing devices & strips and blood-glucose meter. As per application, it is bifurcated into type-1 diabetes and type-2 diabetes. By end user, it is categorized into hospitals & clinics, home care settings, and others. On the contrary, surge in innovation is one of the key trends driving the market growth. Furthermore, the convergence of technology and healthcare promises to make glucose testing seamless, accurate, and patient-centric. In addition, companies are collaborating with healthcare providers and insurance companies to gain a competitive edge in the market.

Moreover, companies are investing in R&D activities and product development to gain a competitive edge in the Italy point-of-care glucose testing market. Furthermore, manufacturers are actively seeking ways to minimize the environmental footprint of their products, incorporating sustainable packaging and implementing strategies to reduce waste in glucose testing process. In addition, key players in the market are collaborating to enhance their product portfolios and expand their market presence. This collaborative approach stimulates competition, fosters innovation, and promotes product diversification, ultimately providing end users with a broader selection of options. The Porter's five forces analysis assesses the competitive strength of the players in the point-of-care glucose testing market. These five forces include the threat of new entrants, the bargaining power of suppliers, the bargaining power of buyers, the threat of substitutes, and competitive rivalry.

The threat of new entrants is high. The bargaining power of suppliers is moderate. The bargaining power of buyers is high. The threat of substitutes is moderate. The competitive rivalry is high. A SWOT analysis of the Italy point-of-care glucose testing market includes strengths, weaknesses, opportunities, and threats. Strengths include industry’s commitment to innovation, rise in prevalence of diabetes, and the market's adaptability. Weaknesses include the regulatory challenges that restrain the market growth and the inherent complexities of managing diabetes. Moreover, market players are often required to make substantial investments in R&D, which is a financial strain. Opportunities include the potential for technological breakthroughs and collaborations with healthcare providers. The market harnesses the power of data analytics and telemedicine to create integrated and efficient solutions for diabetes management. Threats include regulatory changes and reimbursement uncertainties.

Key players operating in the Italy point-of-care glucose testing market include Roche Diagnostics, Abbott Laboratories, Becton, Dickinson and Co., Bayer AG, Nova Biomedical Corporation, Beckman Coulter, Inc., EKF Diagnostics, HDI Diagnostics, Menarini Diagnostics and Arkray, Inc.

 Key Benefits For Stakeholders

Enable informed decision-making process and offer market analysis based on current market situation and estimated future trends.

Analyze the key strategies adopted by major market players in Italy point-of-care glucose testing market.

Assess and rank the top factors that are expected to affect the growth of Italy point-of-care glucose testing market.

Top Player positioning provides a clear understanding of the present position of market players.

Detailed analysis of the Italy point-of-care glucose testing market segmentation assists to determine the prevailing market opportunities.

Identify key investment pockets for various offerings in the market.
Product Benchmarking / Product specification and applications
Upcoming/New Entrant by Regions
New Product Development/ Product Matrix of Key Players
Additional company profiles with specific to client's interest
Additional country or region analysis- market size and forecast
Expanded list for Company Profiles
Historic market data
SWOT Analysis

Key Market Segments

By Product Type

Lancing Devices and Strips
Blood-Glucose Meter
Type
Lifescan OneTouch Ultra and Lifescan OneTouch Verio
Accu-Chek Aviva Plus and Accuchek
Freestyle Lite and Freestyle Precission Neo
Contour Next
Others

By Application

Type-1 Diabetes
Type-2 Diabetes

By End User

Hospitals and Clinics
Home Care Settings
Others

Key Market Players

Roche Diagnostics
Abbott Laboratories
Becton, Dickinson and Co.
Bayer AG
Nova Biomedical Corporation
Beckman Coulter, Inc.
EKF Diagnostics
HDI Diagnostics
Menarini Diagnostics
Arkray, Inc.

Please Note: It will take 7-10 business days to complete the report upon order confirmation. 


CHAPTER 1: INTRODUCTION
1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits to the Stakeholders
1.4. Research Methodology
1.4.1. Primary Research
1.4.2. Secondary Research
1.4.3. Analyst Tools and Models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Impacting Factors
3.2.2. Top Investment Pockets
3.3. Porter’s Five Forces Analysis
3.4. Market Dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
3.5. COVID-19 Impact Analysis on the market
CHAPTER 4: ITALY POINT-OF-CARE GLUCOSE TESTING MARKET, BY PRODUCT TYPE
4.1. Overview
4.1.1. Market Size and Forecast, By Product Type
4.2. Lancing Devices and Strips
4.3. Blood-Glucose Meter
CHAPTER 5: ITALY POINT-OF-CARE GLUCOSE TESTING MARKET, BY APPLICATION
5.1. Overview
5.1.1. Market Size and Forecast, By Application
5.2. Type-1 Diabetes
5.3. Type-2 Diabetes
CHAPTER 6: ITALY POINT-OF-CARE GLUCOSE TESTING MARKET, BY END USER
6.1. Overview
6.1.1. Market Size and Forecast, By End User
6.2. Hospitals and Clinics
6.3. Home Care Settings
6.4. Others
CHAPTER 7: COMPETITIVE LANDSCAPE
7.1. Introduction
7.2. Top winning strategies
7.3. Product Mapping of Top 10 Player
7.4. Competitive Dashboard
7.5. Competitive Heatmap
7.6. Top player positioning, 2022
CHAPTER 8: COMPANY PROFILES
8.1. Roche Diagnostics
8.1.1. Company overview
8.1.2. Key Executives
8.1.3. Company snapshot
8.1.4. Operating business segments
8.1.5. Product portfolio
8.1.6. Business performance
8.1.7. Key strategic moves and developments
8.2. Abbott Laboratories
8.2.1. Company overview
8.2.2. Key Executives
8.2.3. Company snapshot
8.2.4. Operating business segments
8.2.5. Product portfolio
8.2.6. Business performance
8.2.7. Key strategic moves and developments
8.3. Becton, Dickinson and Co.
8.3.1. Company overview
8.3.2. Key Executives
8.3.3. Company snapshot
8.3.4. Operating business segments
8.3.5. Product portfolio
8.3.6. Business performance
8.3.7. Key strategic moves and developments
8.4. Bayer AG
8.4.1. Company overview
8.4.2. Key Executives
8.4.3. Company snapshot
8.4.4. Operating business segments
8.4.5. Product portfolio
8.4.6. Business performance
8.4.7. Key strategic moves and developments
8.5. Nova Biomedical Corporation
8.5.1. Company overview
8.5.2. Key Executives
8.5.3. Company snapshot
8.5.4. Operating business segments
8.5.5. Product portfolio
8.5.6. Business performance
8.5.7. Key strategic moves and developments
8.6. Beckman Coulter, Inc.
8.6.1. Company overview
8.6.2. Key Executives
8.6.3. Company snapshot
8.6.4. Operating business segments
8.6.5. Product portfolio
8.6.6. Business performance
8.6.7. Key strategic moves and developments
8.7. EKF Diagnostics
8.7.1. Company overview
8.7.2. Key Executives
8.7.3. Company snapshot
8.7.4. Operating business segments
8.7.5. Product portfolio
8.7.6. Business performance
8.7.7. Key strategic moves and developments
8.8. HDI Diagnostics
8.8.1. Company overview
8.8.2. Key Executives
8.8.3. Company snapshot
8.8.4. Operating business segments
8.8.5. Product portfolio
8.8.6. Business performance
8.8.7. Key strategic moves and developments
8.9. Menarini Diagnostics
8.9.1. Company overview
8.9.2. Key Executives
8.9.3. Company snapshot
8.9.4. Operating business segments
8.9.5. Product portfolio
8.9.6. Business performance
8.9.7. Key strategic moves and developments
8.10. Arkray, Inc.
8.10.1. Company overview
8.10.2. Key Executives
8.10.3. Company snapshot
8.10.4. Operating business segments
8.10.5. Product portfolio
8.10.6. Business performance
8.10.7. Key strategic moves and developments
LIST OF TABLES
TABLE 01. ITALY POINT-OF-CARE GLUCOSE TESTING MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 02. ITALY POINT-OF-CARE GLUCOSE TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 03. ITALY POINT-OF-CARE GLUCOSE TESTING MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 04. ROCHE DIAGNOSTICS: KEY EXECUTIVES
TABLE 05. ROCHE DIAGNOSTICS: COMPANY SNAPSHOT
TABLE 06. ROCHE DIAGNOSTICS: OPERATING SEGMENTS
TABLE 07. ROCHE DIAGNOSTICS: PRODUCT PORTFOLIO
TABLE 08. ROCHE DIAGNOSTICS: KEY STRATERGIES
TABLE 09. ABBOTT LABORATORIES: KEY EXECUTIVES
TABLE 10. ABBOTT LABORATORIES: COMPANY SNAPSHOT
TABLE 11. ABBOTT LABORATORIES: OPERATING SEGMENTS
TABLE 12. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
TABLE 13. ABBOTT LABORATORIES: KEY STRATERGIES
TABLE 14. BECTON, DICKINSON AND CO.: KEY EXECUTIVES
TABLE 15. BECTON, DICKINSON AND CO.: COMPANY SNAPSHOT
TABLE 16. BECTON, DICKINSON AND CO.: OPERATING SEGMENTS
TABLE 17. BECTON, DICKINSON AND CO.: PRODUCT PORTFOLIO
TABLE 18. BECTON, DICKINSON AND CO.: KEY STRATERGIES
TABLE 19. BAYER AG: KEY EXECUTIVES
TABLE 20. BAYER AG: COMPANY SNAPSHOT
TABLE 21. BAYER AG: OPERATING SEGMENTS
TABLE 22. BAYER AG: PRODUCT PORTFOLIO
TABLE 23. BAYER AG: KEY STRATERGIES
TABLE 24. NOVA BIOMEDICAL CORPORATION: KEY EXECUTIVES
TABLE 25. NOVA BIOMEDICAL CORPORATION: COMPANY SNAPSHOT
TABLE 26. NOVA BIOMEDICAL CORPORATION: OPERATING SEGMENTS
TABLE 27. NOVA BIOMEDICAL CORPORATION: PRODUCT PORTFOLIO
TABLE 28. NOVA BIOMEDICAL CORPORATION: KEY STRATERGIES
TABLE 29. BECKMAN COULTER, INC.: KEY EXECUTIVES
TABLE 30. BECKMAN COULTER, INC.: COMPANY SNAPSHOT
TABLE 31. BECKMAN COULTER, INC.: OPERATING SEGMENTS
TABLE 32. BECKMAN COULTER, INC.: PRODUCT PORTFOLIO
TABLE 33. BECKMAN COULTER, INC.: KEY STRATERGIES
TABLE 34. EKF DIAGNOSTICS: KEY EXECUTIVES
TABLE 35. EKF DIAGNOSTICS: COMPANY SNAPSHOT
TABLE 36. EKF DIAGNOSTICS: OPERATING SEGMENTS
TABLE 37. EKF DIAGNOSTICS: PRODUCT PORTFOLIO
TABLE 38. EKF DIAGNOSTICS: KEY STRATERGIES
TABLE 39. HDI DIAGNOSTICS: KEY EXECUTIVES
TABLE 40. HDI DIAGNOSTICS: COMPANY SNAPSHOT
TABLE 41. HDI DIAGNOSTICS: OPERATING SEGMENTS
TABLE 42. HDI DIAGNOSTICS: PRODUCT PORTFOLIO
TABLE 43. HDI DIAGNOSTICS: KEY STRATERGIES
TABLE 44. MENARINI DIAGNOSTICS: KEY EXECUTIVES
TABLE 45. MENARINI DIAGNOSTICS: COMPANY SNAPSHOT
TABLE 46. MENARINI DIAGNOSTICS: OPERATING SEGMENTS
TABLE 47. MENARINI DIAGNOSTICS: PRODUCT PORTFOLIO
TABLE 48. MENARINI DIAGNOSTICS: KEY STRATERGIES
TABLE 49. ARKRAY, INC.: KEY EXECUTIVES
TABLE 50. ARKRAY, INC.: COMPANY SNAPSHOT
TABLE 51. ARKRAY, INC.: OPERATING SEGMENTS
TABLE 52. ARKRAY, INC.: PRODUCT PORTFOLIO
TABLE 53. ARKRAY, INC.: KEY STRATERGIES
LIST OF FIGURES
FIGURE 01. ITALY POINT-OF-CARE GLUCOSE TESTING MARKET, 2022-2032
FIGURE 02. SEGMENTATION OF ITALY POINT-OF-CARE GLUCOSE TESTING MARKET, 2022-2032
FIGURE 03. TOP INVESTMENT POCKETS IN ITALY POINT-OF-CARE GLUCOSE TESTING MARKET (2023-2032)
FIGURE 04. PORTER FIVE-1
FIGURE 05. PORTER FIVE-2
FIGURE 06. PORTER FIVE-3
FIGURE 07. PORTER FIVE-4
FIGURE 08. PORTER FIVE-5
FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: ITALY POINT-OF-CARE GLUCOSE TESTING MARKET
FIGURE 10. ITALY POINT-OF-CARE GLUCOSE TESTING MARKET,BY PRODUCT TYPE, 2022 ($MILLION)
FIGURE 11. ITALY POINT-OF-CARE GLUCOSE TESTING MARKET,BY APPLICATION, 2022 ($MILLION)
FIGURE 12. ITALY POINT-OF-CARE GLUCOSE TESTING MARKET,BY END USER, 2022 ($MILLION)
FIGURE 13. TOP WINNING STRATEGIES, BY YEAR
FIGURE 14. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 15. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 16. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 17. COMPETITIVE DASHBOARD
FIGURE 18. COMPETITIVE HEATMAP: ITALY POINT-OF-CARE GLUCOSE TESTING MARKET
FIGURE 19. TOP PLAYER POSITIONING, 2022
FIGURE 20. ROCHE DIAGNOSTICS: NET SALES, 2020-2022* ($MILLION)
FIGURE 21. ROCHE DIAGNOSTICS: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 22. ROCHE DIAGNOSTICS: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 23. ABBOTT LABORATORIES: NET SALES, 2020-2022* ($MILLION)
FIGURE 24. ABBOTT LABORATORIES: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 25. ABBOTT LABORATORIES: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 26. BECTON, DICKINSON AND CO.: NET SALES, 2020-2022* ($MILLION)
FIGURE 27. BECTON, DICKINSON AND CO.: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 28. BECTON, DICKINSON AND CO.: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 29. BAYER AG: NET SALES, 2020-2022* ($MILLION)
FIGURE 30. BAYER AG: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 31. BAYER AG: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 32. NOVA BIOMEDICAL CORPORATION: NET SALES, 2020-2022* ($MILLION)
FIGURE 33. NOVA BIOMEDICAL CORPORATION: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 34. NOVA BIOMEDICAL CORPORATION: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 35. BECKMAN COULTER, INC.: NET SALES, 2020-2022* ($MILLION)
FIGURE 36. BECKMAN COULTER, INC.: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 37. BECKMAN COULTER, INC.: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 38. EKF DIAGNOSTICS: NET SALES, 2020-2022* ($MILLION)
FIGURE 39. EKF DIAGNOSTICS: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 40. EKF DIAGNOSTICS: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 41. HDI DIAGNOSTICS: NET SALES, 2020-2022* ($MILLION)
FIGURE 42. HDI DIAGNOSTICS: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 43. HDI DIAGNOSTICS: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 44. MENARINI DIAGNOSTICS: NET SALES, 2020-2022* ($MILLION)
FIGURE 45. MENARINI DIAGNOSTICS: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 46. MENARINI DIAGNOSTICS: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 47. ARKRAY, INC.: NET SALES, 2020-2022* ($MILLION)
FIGURE 48. ARKRAY, INC.: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 49. ARKRAY, INC.: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)

$3,570
$2,670
$4,560
$5,550

Research Assistance

US: 800.298.5699
Int'l: +1.240.747.3093
Live help
Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Other tasks

Cookie Settings